17 results about "Bone marrow source" patented technology

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The invention belongs to the technical field of medical materials and tissue regeneration engineering, and provides a composite hydrogel prepolymerization solution and application thereof, and composite hydrogel and application thereof. The composite hydrogel pre-polymerization liquid provided by the invention is prepared from the following components in concentration: 5 to 10 w / v percent of methacrylic anhydride gelatin, 1 to 4 w / v percent of methacrylated hyaluronic acid, 0.5 to 1.5 w / v percent of hectorite, 0.5 to 1.5 w / v percent of a photoinitiator and 20 to 100 nmol / L of sphingosine-1-phosphoric acid loaded nano vesicles based on sphingosine-1-phosphoric acid, the nano vesicles are formed by bone marrow-derived macrophages. The composite hydrogel formed by the composite hydrogel pre-polymerization liquid has good biocompatibility and controllable release performance, can form a stable barrier environment on a wound surface, and significantly accelerates the wound surface healing process through the dual effects of immune regulation and revascularization.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.

The present disclosure relates to a composition for three-dimensional cell and / or organoid culture, comprising a phase-changing matrix comprising a partially ordered polypeptide, and a plurality of cells encapsulated in the matrix. In embodiments, the plurality of cells comprises one or more cell types, including at least one cell type selected from the group consisting of: bone-marrow derived mesenchymal stem cells and adipose-derived mesenchymal stem cells. In embodiments, the one or more cell types comprises mesenchymal stem cells, the partially ordered polypeptide comprises at least one chemically-interactive sequence such as arginylglycylaspartic acid (RGD) sequence, the matrix forms a porous network when heated above a transition temperature, and the partially-ordered polypeptide comprises a plurality of structured domains, and a plurality of disordered domains.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The invention discloses a preparation method and application of a novel macrophage for treating myocardial infarction, and belongs to the fields of cell engineering, nanotechnology, material science, immunology and the like. According to the invention, bone marrow-derived macrophages are induced to be polarized to M2 type and are subjected to magnetic modification, so that the macrophages are endowed with the capability of efficiently expressing vascular endothelial growth factors, Mag M2-M-VEGF cells are obtained, and proliferation of endothelial cells and formation of collateral vessels are promoted through local high expression of VEGF at a myocardial infarction part, so that local ischemia injury is relieved. According to the invention, precise targeted delivery of cells is realized, local inflammatory response is inhibited, and blood perfusion in an infarction area is improved. The medicine is endowed with magnetic targeting capacity by internalizing Fe3O4 NPs and is accurately enriched in myocardial infarction tissue under the guidance of a magnetic field, M2 type polarization inhibits pro-inflammatory reaction by reducing pro-inflammatory factor release and releasing a large amount of anti-inflammatory factors, and meanwhile, VEGF is specifically secreted, angiogenesis of an infarction part is promoted, and the capillary density of an infarction region is effectively increased.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention discloses an immortalized goat bone marrow-derived macrophage for expressing an SV40LT gene and application of the immortalized goat bone marrow-derived macrophage, and belongs to the technical field of bioengineering. The immortalized goat bone marrow-derived macrophage provided by the invention is obtained by knocking an immortalized gene SV40LT into a primary goat bone marrow-derived macrophage ROSA26 site through a CRISPR-Cas 9 system, and the immortalized goat macrophage provided by the invention is an immortalized goat macrophage cell strain which is suitable for being infected with salmonella and brucella and can be continuously and stably passaged; the method can be effectively applied to immunological research on goat brucella infection resistance and production of brucella vaccines.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The present invention relates to a composition comprising C-C motif chemokine ligand 5 (CCL5) for promoting the activation of bone marrow-derived stem cells. It is identified that, when CCL5, which is a niche-enhancing factor, is injected together with growth related oncogene beta (GROβ), which is known to promote the mobilization of hematopoietic stem cells from the bone marrow into peripheral blood, and AMD3100, which is a CXCR4 antagonist, the migration of hematopoietic stem cells from bone marrow to peripheral blood increases, and the engraftment rate also increases when the hematopoietic stem cells are injected into recipients undergoing bone marrow transplantation. Therefore, the CCL5 protein, GROβ, and the CXCR4 antagonist AMD3100 are provided as a composition for promoting the activation of bone marrow-derived stem cells, and thus bone marrow-derived stem cells activated thereby is provided as a novel therapeutic means for bone marrow diseases requiring bone marrow transplantation.

Disclosed herein are methods of treating complex regional pain syndrome in a subject by administering a therapeutic MSC secretory group product prepared by a method comprising culturing a bone marrow-derived MSC under conditions comprising an oxygen tension of less than 5% and a culture medium having a pH of less than 7.

Disclosed herein are methods of treating amyotrophic lateral sclerosis in a subject by administering a therapeutic MSC secretory group product prepared by a method comprising culturing a bone marrow-derived MSC under conditions comprising an oxygen tension of less than 5% and a culture medium having a pH of less than 7.

The invention belongs to the technical field of biological detection, and provides a chemokine detection kit and a preparation method and application thereof, and the detection kit comprises a capture antibody, a detection antibody, a mixed protein standard substance, a diluent and a washing buffer solution. The capture system is used for preparing a capture antibody coupled with a fluorescence coding microsphere by coupling a biotinylated antibody with a fluorescence microsphere coated with biotin, and the detection system is used for preparing a fluorescence labeled antibody by coupling derivatized phycoerythrin PE-SMCC with a specific thioether bond of a sulfhydrylated antibody. The mixed protein standard substance adopts a freeze-drying protection system containing BSA, trehalose and the like. The single hole of the kit can synchronously detect various cytokines, the sample dosage is only 25 microliters, the kit is suitable for detecting chemotactic factors in a mouse in-vitro bone marrow-derived macrophage (BMDM) polarization model, compared with a traditional ELISA method, the efficiency is improved by 10 times, the cost is reduced, and the kit has the remarkable advantages of high flux, wide linear range and high stability.

This invention belongs to the field of regenerative medicine technology, specifically relating to bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1, their preparation method, and applications. The steps are as follows: Primary mouse bone marrow mononuclear precursor cells are cultured in expansion medium for 7 days to obtain macrophages, with the medium changed every 2-3 days during this period; on the 7th day, the expansion medium is replaced with a high-efficiency induction medium and cultured for 46-50 hours to obtain bone marrow-derived macrophages expressing CD301b, TIMD4, and LYVE-1. This invention, through a time-series strategy of TGF-β pre-induction combined with IL-4 / IL-5 / IL-13 synergistic induction, can significantly enhance the expression levels of CD301b, TIMD4, and LYVE-1 in BMDM, making their function close to that of natural cardiac resident macrophages, and effectively exerting anti-inflammatory, repair-promoting, and ventricular remodeling-inhibiting effects after AMI.

The application belongs to the technical field of biomedicine, and discloses a construction method of a mouse model simulating senile osteoarthritis and application thereof, wherein mouse bone marrow cells are induced to differentiate into bone marrow-derived macrophages in vitro, the macrophages are treated with an induction medium containing 100nM doxorubicin for 2 days, and then cultured in a conventional medium for 5 days to obtain senescent macrophages with a stable senescence phenotype; 1x10 6 The senescent macrophages are injected into the knee joint cavity of a mouse once a week for a total of 4 times to induce chronic low-grade inflammation and characteristic osteoarthritis lesions in the joint. The model constructed by the application has high pathological simulation degree, good repeatability, and a modeling cycle of only 4 weeks, thereby reducing the interference of acute injury factors, and can be widely applied to the research on pathogenesis of senile osteoarthritis, screening of therapeutic targets, and evaluation of the efficacy of candidate drugs.

The invention discloses an exosome vesicle for enhancing the curative effect of liver cancer immunotherapy as well as a preparation method and application of the exosome vesicle. The invention provides an application of an exosome vesicle containing miR-32-5p in preparation of a medicine for treating liver cancer or enhancing a liver cancer immunotherapy curative effect. A preparation method of the exosome vesicle comprises the following steps: introducing a miR-32-5p simulant into bone marrow-derived macrophage (BMDM) through transfection, and constructing a BMDM cell line of stable overexpression miR-32-5p, culturing, collecting cell culture supernatant, and separating and purifying to obtain the exosome vesicle. In-vivo and in-vitro experiments show that the exosome miR-32-5p has the functions in TME regulation, immune regulation and HCC progress, the exosome miR-32-5p can enhance HCC immunotherapy, a better treatment strategy is provided for clinical treatment of HCC, especially TACE drug-resistant HCC, and the exosome miR-32-5p has a good application prospect.

The present invention discloses a tumor recurrence risk stratification kit based on bone marrow spleen neutrophil ARG1 expression, and relates to the technical field of tumor recurrence risk stratification kits, the tumor recurrence risk stratification kit comprises: a flow cytometry detection module containing the following antibodies coupled with a fluorescent dye: an anti-human CD62L antibody for identifying bone marrow-derived neutrophil; the anti-human CD44 antibody is used for recognizing spleen-derived neutrophil; the anti-human ARG1 antibody is used for detecting the ARG1 expression of the neutrophil; the enzyme-linked immunosorbent assay (ELISA) module contains a reagent for quantitatively detecting the concentration of ARG1 protein in a neutrophil culture supernatant. By accurately determining the expression difference of bone marrow and spleen neutrophil ARG1 of a postoperative patient, dual dimensions of a source function are directly associated with a tumor recurrence risk for the first time; the detection sensitivity and the operation convenience are ensured by utilizing a flow type platform and an ELISA (Enzyme-Linked Immuno Sorbent Assay) double platform; and the multi-center consistency and real-time clinical decision support are further ensured by a matched quality control system and a cloud intelligent interpretation platform.